HC Wainwright Comments on Galectin Therapeutics Inc.’s Q1 2025 Earnings (NASDAQ:GALT)

Galectin Therapeutics Inc. (NASDAQ:GALT) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a note issued to investors on Friday, August 16th. HC Wainwright analyst E. Arce forecasts that the company will earn ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.53) EPS and FY2027 earnings at $1.29 EPS.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04).

Separately, StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 18th.

Galectin Therapeutics Trading Up 5.9 %

GALT opened at $2.32 on Monday. The stock’s 50-day moving average price is $2.35 and its 200 day moving average price is $2.54. Galectin Therapeutics has a 12-month low of $1.55 and a 12-month high of $4.27. The firm has a market cap of $144.49 million, a price-to-earnings ratio of -3.14 and a beta of 0.63.

Hedge Funds Weigh In On Galectin Therapeutics

Hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC increased its holdings in Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after purchasing an additional 367,610 shares during the period. Wealthspire Advisors LLC increased its holdings in Galectin Therapeutics by 116.7% during the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock worth $952,000 after purchasing an additional 214,512 shares during the period. Bank of New York Mellon Corp purchased a new stake in Galectin Therapeutics during the 2nd quarter worth about $146,000. Vanguard Group Inc. increased its holdings in Galectin Therapeutics by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after purchasing an additional 38,037 shares during the period. Finally, Squarepoint Ops LLC increased its holdings in Galectin Therapeutics by 75.4% during the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock worth $190,000 after purchasing an additional 36,139 shares during the period. Institutional investors and hedge funds own 11.68% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.